What Happens If You Stop Tirzepatide?

One of the most important and least glamorous facts about tirzepatide is that it works for as long as you take it. It is not a short course that resets your metabolism — it is a treatment for chronic conditions, and stopping it tends to reverse much of the benefit. The clearest evidence for this comes from a dedicated withdrawal trial, SURMOUNT-4. This guide explains what that trial found and what it means for how the drug is used.

The SURMOUNT-4 withdrawal trial

SURMOUNT-4 was designed specifically to answer the "what if you stop" question. All participants first took tirzepatide for a 36-week lead-in period, losing weight as expected. They were then randomized either to continue tirzepatide or to switch to placebo, and were followed to see what happened next¹.

The result was unambiguous. Participants who switched to placebo regained a substantial portion of the weight they had lost, while those who continued tirzepatide kept losing or maintained their loss¹. In other words, the weight loss was not "locked in" by the initial treatment period — it depended on staying on the drug.

Why weight tends to come back

This pattern is not unique to tirzepatide; it reflects how the medicine works. Tirzepatide acts on incretin pathways — the GIP and GLP-1 receptors — that influence appetite, fullness, and how the body handles food². While you take it, hunger and food intake are reduced. When the drug is withdrawn, those pharmacological effects fade, appetite signals return toward their prior state, and weight tends to drift back up. Obesity is understood as a chronic, relapsing condition, which is why effective treatment generally needs to be ongoing rather than a one-time fix.

What this means in practice

The honest takeaway is that tirzepatide should be thought of as a long-term therapy, not a temporary intervention. That framing matches the FDA labeling: it is indicated to reduce excess body weight and to maintain that reduction long term, as an adjunct to a reduced-calorie diet and increased physical activity³. The maintenance language in the label is deliberate — the drug is approved both to take weight off and to keep it off with continued use.

This does not mean stopping is forbidden or dangerous, and decisions about continuing, pausing, or stopping should be made with a prescriber based on your goals, response, side effects, and circumstances. But it does mean going in with realistic expectations: the results are real and well-documented, and they are also contingent on ongoing treatment.

It also reframes how to judge "success." Because the benefit is maintained rather than banked, a sensible plan treats the lowest effective dose that keeps weight stable as a reasonable long-term target, rather than aiming to climb to the maximum, lose quickly, and then quit. For people whose primary indication is type 2 diabetes, the same logic applies to blood-glucose control: the glycemic improvements that tirzepatide produces are sustained by continued use, and stopping would be expected to let HbA1c drift back toward its untreated level over time. None of this is a reason to avoid the drug; it is simply the correct mental model for a chronic-disease medication.

Tapering and stopping

There is no withdrawal syndrome from stopping tirzepatide in the way there is with some medications, but a few practical points are worth knowing. Side effects of the drug itself are dominated by gastrointestinal events that occur mainly during dose escalation and at higher doses⁴; those generally ease rather than worsen if a dose is lowered or stopped. The main consequence of stopping is the gradual return of appetite and the weight regain documented in SURMOUNT-4¹. If you are considering stopping — whether because of side effects, cost, or a treatment break — that is a conversation to have with your prescriber, who can advise on dose adjustments and on monitoring after stopping.

The bottom line

Tirzepatide is a genuinely effective treatment, but its benefits are maintained through ongoing use, not banked from a short course. SURMOUNT-4 showed that switching from tirzepatide to placebo led to substantial weight regain, while continuing the drug maintained the loss¹. That is why it is framed — in both the trials and the FDA label — as a long-term, maintenance therapy³. For the full evidence base, see the tirzepatide evidence guide; for the dosing schedule and side effects, see the tirzepatide dosing ladder and side effects guide; and to weigh your options, start with our best tirzepatide overview.